CNP-103 tolerogenic nanoparticles
What it is
An antigen-specific immune-tolerance candidate in a recruiting Phase 1b/2a trial. An ADA 2026 abstract reports early tolerability in the first six adults, without a C-peptide efficacy result.
Editorial review: . What was checked and what remains uncertain.
Latest dated source in the citation list: 2026-09-11. This is the source’s date, not a new review of every claim.
Trial status, labels and access can change between reviews.
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Beta-cell preservation: The conference report does not report a clinical C-peptide preservation result.[2]
- Important harms and treatment burden
- Safety: The first six adults had no reported serious events after early dosing; this small conference report cannot establish overall safety.[2]
- Approval and country access
- An antigen-specific immune-tolerance candidate in a recruiting Phase 1b/2a trial. An ADA 2026 abstract reports early tolerability in the first six adults, without a C-peptide efficacy result.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: The initial cohort report cannot establish lasting tolerance or preserved insulin secretion.[2]
Research status alone does not establish approval, clinical benefit or local availability. This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 12 × 30 + 10 × 20 + 30 × 20 + 25 × 10 + 22 × 20 = 1850; divide by total weight 100. Unrounded weighted result: 18.5.
The conference report does not report a clinical C-peptide preservation result.[2]
The initial cohort report cannot establish lasting tolerance or preserved insulin secretion.[2]
The first six adults had no reported serious events after early dosing; this small conference report cannot establish overall safety.[2]
The protocol selects ages 12–35 within 180 days of diagnosis with residual C-peptide; adolescent cohorts follow adult safety review.[1]
Recruiting first-in-human Phase 1b/2a trial, 72 participants planned; the reported cohort is much smaller.[1]
The full picture
Intended mechanism
COUR describes CNP-103 as a nanoparticle-based therapy intended to induce antigen-specific immune tolerance and protect remaining beta cells. This is a sponsor-described design, not demonstrated selective immune control in people with T1D. Its reported Fast Track designation is not marketing approval.1
What has actually reported
ADA 2026 abstract 2419-P describes the first six adults in the 100 mg cohort after day-1 and day-8 dosing. It reports no infusion interruptions or serious adverse events. Reported events included sinus discomfort, presyncope, reduced neutrophil count and low vitamin D; none was judged product-related. This is a small conference abstract, not a full clinical safety dataset or an efficacy result.2
The full randomized trial plans 72 participants, including adult and adolescent dose cohorts followed by expansion. The September registry update lists recruiting with primary completion estimated for December 2026. Its calendar and enrolment target are not outcome data. Sponsor and registry agree on active recruitment, but each site must confirm age-band eligibility and availability.3 4
Sources
- [1]NCT06783309 — study record · registry · 2026-09-11 — Registry update date; retrieved 16 September 2026. Registry registration is not proof of clinical benefit.
- [2]ADA 2026 abstract 2419-P: CNP-103 first-in-human study · conference · 2026-06-05 — Early six-adult cohort safety report; no C-peptide efficacy result and no full peer-reviewed clinical report.
- [3]COUR pipeline — CNP-103 intended immune-tolerance mechanism · manufacturer
- [4]COUR CNP-103 clinical trial information · manufacturer